Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $326 from $309 and keeps an Equal Weight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen price target raised to $351 from $347 at Guggenheim
- Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating
- Amgen price target raised to $325 from $319 at Truist
- Viridian Therapeutics price target lowered to $36 from $40 at Truist
- Viridian Therapeutics price target lowered to $31 from $37 at Wedbush